FDA Approved: ALPRAZOLAM EXTENDED RELEASE — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for an extended-release formulation of alprazolam, adding the extended-release dosage form under the ANDA for Actavis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder
• Panic Disorder

Drugs mentioned

• ALPRAZOLAM EXTENDED RELEASE (alprazolam)

Snippet

SUPPL AP for ALPRAZOLAM EXTENDED RELEASE (ALPRAZOLAM)